B
Barry R. Davis
Researcher at University of Texas at Austin
Publications - 351
Citations - 50989
Barry R. Davis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Chlorthalidone & Amlodipine. The author has an hindex of 78, co-authored 342 publications receiving 47899 citations. Previous affiliations of Barry R. Davis include Tulane University & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Change in Depression as a Precursor of Cardiovascular Events
Sylvia Wassertheil-Smoller,William B. Applegate,Kenneth G. Berge,Chee-Jen Chang,Barry R. Davis,Richard H. Grimm,John B. Kostis,Sara L. Pressel,Eleanor Schron +8 more
TL;DR: A significant and substantial excess risk of death and stroke or myocardial infarction was associated with an increase in depressive symptoms over time, which may be a marker for subsequent major disease events and warrants the attention of physicians to such mood changes.
Journal ArticleDOI
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes
John B. Kostis,Alan C. Wilson,Ronald S. Freudenberger,Nora M. Cosgrove,Sara L. Pressel,Barry R. Davis +5 more
TL;DR: Chlorthalidone-based treatment improved long-term outcomes, especially among subjects who had diabetes, which had no significant increase in CV events and had a better prognosis than did those who had preexisting diabetes.
Journal ArticleDOI
Reduction of Stroke Events With Pravastatin The Prospective Pravastatin Pooling (PPP) Project
Robert P. Byington,Barry R. Davis,Jonathan F. Plehn,Harvey D. White,Jennifer Baker,Stuart M. Cobbe,James Shepherd +6 more
TL;DR: Pravastatin reduced the risk of stroke over a wide range of lipid values among patients with documented coronary disease, due to a reduction in nonfatal nonhemorrhagic strokes.
Journal ArticleDOI
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.
Jackson T. Wright,William C. Cushman,Barry R. Davis,Joshua I. Barzilay,Pedro J. Colon,Debra Egan,Tracy Lucente,Chuke Nwachuku,Sara L. Pressel,Frans H. H. Leenen,Joseph P. Frolkis,Rebecca Letterer,Sandra M. Walsh,Jonathan N. Tobin,Grant E Deger +14 more
TL;DR: The AllHAT trial as mentioned in this paper is a randomized clinical outcome trial of antihypertensive and lipid-lowering therapy in a diverse population (including substantial numbers of women and minorities) of 42,419 high-risk hypertensives aged > or = 55 years with a planned mean follow-up of 6 years.
Journal ArticleDOI
Diagnostic Marker Cooperative Study for the Diagnosis of Myocardial Infarction
Janice L. Zimmerman,Robert E. Fromm,Denise Meyer,Ann Boudreaux,Chuan Chuan C Wun,Richard W. Smalling,Barry R. Davis,Gabriel B. Habib,Robert Roberts +8 more
TL;DR: The CK-MB subform assay alone or in combination with a troponin reliably triages patients with chest pain and should lead to improved therapy and reduced cost.